公开(公告)号：US12082581B2

公开(公告)日：2024-09-10

申请号：US17623129

申请日：2020-06-26

申请人： SUMITOMO CHEMICAL COMPANY, LIMITED

发明人： Hiroto Tamashima

IPC分类号： A01N37/38 ,  A01N37/36 ,  A01N37/50 ,  A01N43/08 ,  A01N43/10 ,  A01N43/20 ,  A01N43/40 ,  A01N43/60 ,  A01N43/78 ,  A01N43/80 ,  A01N47/10 ,  A01N47/16 ,  A01N47/22 ,  A01N55/00 ,  A01N55/08 ,  A61P1/00 ,  A61P3/00 ,  A61P7/00 ,  C07C69/712 ,  C07C69/734 ,  C07C69/736 ,  C07C251/40 ,  C07C255/54 ,  C07C271/40 ,  C07C271/44 ,  C07C271/56 ,  C07C271/58 ,  C07C307/02 ,  C07C309/65 ,  C07C309/66 ,  C07C309/73 ,  C07C333/04 ,  C07D207/08 ,  C07D213/30 ,  C07D213/61 ,  C07D241/16 ,  C07D261/18 ,  C07D277/24 ,  C07D295/088 ,  C07D295/205 ,  C07D303/23 ,  C07D307/12 ,  C07D307/42 ,  C07D333/16 ,  C07F7/08

CPC分类号： A01N37/38 ,  A01N37/50 ,  A01N43/08 ,  A01N43/10 ,  A01N43/20 ,  A01N43/40 ,  A01N43/60 ,  A01N43/78 ,  A01N43/80 ,  A01N55/00 ,  C07C69/736 ,  C07C251/40 ,  C07D213/61 ,  C07D241/16 ,  C07D261/18 ,  C07D277/24 ,  C07D295/088 ,  C07D303/23 ,  C07D307/12 ,  C07D333/16 ,  C07F7/081

摘要： The present invention provides a compound represented by formula (I) [wherein L represents an oxygen atom or CH2, E represents a C2-C10 chain hydrocarbon group or the like, R1 represents a C1-C3 chain hydrocarbon group or the like, R2 represents a C1-C3 chain hydrocarbon group or the like, and n is 0, 1, 2 or 3.] or its N oxide or agriculturally acceptable salt, which is a compound that have excellent pests controlling effects.

公开(公告)号：US20240244958A1

公开(公告)日：2024-07-18

申请号：US18382858

申请日：2023-10-23

申请人： LG DISPLAY CO., LTD.

发明人： Jicheol SHIN ,  Su Bin AHN

IPC分类号： H10K85/60 ,  C07C255/47 ,  C07D213/61 ,  C09K11/06

CPC分类号： H10K85/615 ,  C07C255/47 ,  C07D213/61 ,  C09K11/06 ,  H10K85/654 ,  H10K50/12

摘要： Embodiments of the disclosure relate to an organic light emitting element and a display device. Specifically, there may be provided an organic light emitting element including a compound represented by chemical formula 1 to provide excellent efficiency, long lifespan or low driving voltage and a display device including the organic light emitting element.

公开(公告)号：US20240239739A1

公开(公告)日：2024-07-18

申请号：US17870490

申请日：2022-07-21

申请人： AurimMed Pharma, Inc.

发明人： Amir Pesyan ,  Manuel F. Balandrin

IPC分类号： C07C233/11 ,  A61P25/16 ,  A61P25/28 ,  C07C233/58 ,  C07C235/28 ,  C07C235/34 ,  C07C235/36 ,  C07C237/20 ,  C07C237/22 ,  C07C255/54 ,  C07D207/16 ,  C07D211/16 ,  C07D211/60 ,  C07D211/62 ,  C07D213/56 ,  C07D213/61 ,  C07D213/643 ,  C07D295/155 ,  C07D295/185 ,  C07D307/81 ,  C07D317/60 ,  C07D319/18

CPC分类号： C07C233/11 ,  A61P25/16 ,  A61P25/28 ,  C07C233/58 ,  C07C235/28 ,  C07C235/34 ,  C07C235/36 ,  C07C237/20 ,  C07C237/22 ,  C07C255/54 ,  C07D207/16 ,  C07D211/16 ,  C07D211/60 ,  C07D211/62 ,  C07D213/56 ,  C07D213/61 ,  C07D213/643 ,  C07D295/155 ,  C07D295/185 ,  C07D307/81 ,  C07D317/60 ,  C07D319/18

摘要： A series of novel amides showing broad pharmaceutical activity. Compounds described herein are effective as anticonvulsants, chemical countermeasures, and analgesics. Such compounds also show, neuroprotective/neuroreparative effects and activity against spinal muscular atrophy. Such pharmaceutically active compounds show utility in the treatment of central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's, ALS, and Huntington's disease) spasticity, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), and/or traumatic brain and/or spinal cord injuries.

公开(公告)号：US12017975B2

公开(公告)日：2024-06-25

申请号：US17966227

申请日：2022-10-14

申请人： THE UNIVERSITY OF BRITISH COLUMBIA

发明人： Artem Tcherkassov ,  Paul S. Rennie ,  Fuqiang Ban ,  Eric J. J. Leblanc ,  Lavinia A. Carabet ,  Nada Lallous ,  Kriti Singh ,  Helene Morin ,  Anh-Tien Ton

IPC分类号： C07C237/22 ,  C07C255/66 ,  C07C275/30 ,  C07C311/18 ,  C07C335/16 ,  C07C335/18 ,  C07D211/42 ,  C07D213/40 ,  C07D213/61 ,  C07D231/14 ,  C07D239/42 ,  C07D241/24 ,  C07D249/08 ,  C07D261/08 ,  C07D265/30 ,  C07D265/36 ,  C07D277/36 ,  C07D307/14 ,  C07D311/16 ,  C07D333/20 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D409/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07D471/04

CPC分类号： C07C237/22 ,  C07C255/66 ,  C07C275/30 ,  C07C311/18 ,  C07C335/16 ,  C07C335/18 ,  C07D211/42 ,  C07D213/40 ,  C07D213/61 ,  C07D231/14 ,  C07D239/42 ,  C07D241/24 ,  C07D249/08 ,  C07D261/08 ,  C07D265/30 ,  C07D265/36 ,  C07D277/36 ,  C07D307/14 ,  C07D311/16 ,  C07D333/20 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D409/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07D471/04

摘要： Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia.

公开(公告)号：US20240182418A1

公开(公告)日：2024-06-06

申请号：US18493017

申请日：2023-10-24

申请人： Modern Biosciences Limited

发明人： Lisa PATEL ,  Stephen Allan SMITH

IPC分类号： C07D213/61 ,  C07C317/22 ,  C07C317/36 ,  C07D213/06

CPC分类号： C07D213/61 ,  C07C317/22 ,  C07C317/36 ,  C07D213/06

摘要： The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds (collectively referred to herein as CHMSA compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, hidradenitis suppurativa, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

公开(公告)号：US11952355B2

公开(公告)日：2024-04-09

申请号：US17259565

申请日：2019-06-17

申请人： Shenyang Sinochem Agrochemicals R&D Co., Ltd.

发明人： Hongfei Wu ,  Xueming Cheng ,  Libao Xu ,  Chunxiao Guo ,  Jingbo Xu ,  Ningning Sun ,  Haibo Yu

IPC分类号： C07D277/24 ,  C07C253/20 ,  C07C253/30 ,  C07C255/64 ,  C07D213/61 ,  C07D215/14

CPC分类号： C07D277/24 ,  C07C253/20 ,  C07C253/30 ,  C07C255/64 ,  C07D213/61 ,  C07D215/14

摘要： Provided are a method of preparing a malononitrile oxime ether compound and an intermediate compound. The malononitrile oxime ether compound has a structure as shown in formula (VII), wherein W is selected from aryl or heteroaryl. The preparation method comprises: reacting a first raw material with a second raw material in the presence of a first solvent and a catalyst to obtain the intermediate compound, wherein the first raw material has a structure as shown in formula (IV), and the second raw material has a structure as shown in formula (V); and subjecting the intermediate compound, and a dehydrant to a dehydration reaction in the present of a second solvent to obtain the malononitrile oxime ether compound. Furthermore, the malononitrile oxime ether compound is obtained through one-step dehydration reaction. using the preparation method, is advantageous for improving the yield of malononitrile oxime ethers and reducing the cost.

公开(公告)号：US11793771B2

公开(公告)日：2023-10-24

申请号：US17838400

申请日：2022-06-13

申请人： CHEMOCENTRYX, INC.

发明人： Christopher Lange ,  Viengkham Malathong ,  Darren J. McMurtrie ,  Sreenivas Punna ,  Rajinder Singh ,  Ju Yang ,  Penglie Zhang

IPC分类号： A61K31/085 ,  C07D211/40 ,  A61P35/00 ,  C07C215/12 ,  C07F5/02 ,  C07D401/14 ,  C07D213/30 ,  C07D405/12 ,  C07C229/22 ,  C07D319/18 ,  C07D417/12 ,  A61K45/06 ,  C07C235/42 ,  C07C235/20 ,  C07D239/42 ,  C07C255/54 ,  C07D213/61 ,  C07D413/12 ,  C07D205/04 ,  A61P31/00 ,  C07D237/08 ,  C07D401/12 ,  C07D213/85 ,  C07D239/30 ,  C07D405/14 ,  C07D401/04 ,  C07D409/12 ,  C07D213/80 ,  A61P29/00 ,  C07C317/22 ,  C07F9/58 ,  A61K31/015 ,  A61K31/03 ,  A61K31/277 ,  A61K38/00 ,  C07C43/168 ,  A61K31/36 ,  A61K31/44 ,  A61K31/505 ,  A61K47/34

CPC分类号： A61K31/085 ,  A61K31/015 ,  A61K31/03 ,  A61K31/277 ,  A61K38/00 ,  A61K45/06 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  C07C43/168 ,  C07C215/12 ,  C07C229/22 ,  C07C235/20 ,  C07C235/42 ,  C07C255/54 ,  C07C317/22 ,  C07D205/04 ,  C07D211/40 ,  C07D213/30 ,  C07D213/61 ,  C07D213/80 ,  C07D213/85 ,  C07D237/08 ,  C07D239/30 ,  C07D239/42 ,  C07D319/18 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07F5/025 ,  C07F9/58 ,  A61K31/36 ,  A61K31/44 ,  A61K31/505 ,  A61K47/34 ,  C07C2601/02 ,  C07C2602/08 ,  Y02A50/30

摘要： Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II):






including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US20230295092A1

公开(公告)日：2023-09-21

申请号：US18186043

申请日：2023-03-17

申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM ,  RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

发明人： Jens Cardinale ,  Martin Schaefer ,  Klaus Kopka ,  Matthias Eder ,  Ulrike Bauder-Wuest ,  Michael Eisenhut ,  Martina Benesova ,  Uwe Haberkorn ,  Frederik L. Giesel

IPC分类号： C07D213/61 ,  A61K51/04 ,  C07B59/00 ,  G01N33/574 ,  C07K7/02 ,  A61P35/00

CPC分类号： C07D213/61 ,  A61K51/0455 ,  C07B59/002 ,  G01N33/57434 ,  A61K51/04 ,  C07K7/02 ,  A61P35/00 ,  A61K38/00

摘要： The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.

公开(公告)号：US20230247900A1

公开(公告)日：2023-08-03

申请号：US18002003

申请日：2021-06-18

申请人： Novaled GmbH

发明人： Max Peter Nüllen ,  Benjamin Schulze ,  Jakob Jacek Wudarczyk

IPC分类号： H10K85/60 ,  C07C255/35 ,  C07C255/51 ,  C07D213/57 ,  C07D213/61 ,  C07D239/30 ,  C07D239/26

CPC分类号： H10K85/654 ,  C07C255/35 ,  H10K85/60 ,  C07C255/51 ,  C07D213/57 ,  C07D213/61 ,  C07D239/30 ,  C07D239/26 ,  C07C2601/02 ,  H10K50/11

摘要： The present invention relates to a compound of formula (I) and an organic electronic device comprising a semiconductor layer which comprises a compound of formula (I).

公开(公告)号：US11713324B2

公开(公告)日：2023-08-01

申请号：US17126581

申请日：2020-12-18

申请人： Neurocrine Biosciences, Inc.

发明人： Graham Beaton ,  Mi Chen ,  Timothy Richard Coon ,  Todd Ewing ,  Wanlong Jiang ,  Willy Moree ,  Martin Rowbottom ,  Warren Wade ,  Liren Zhao ,  Richard Lowe ,  Nicole Smith ,  Neil Ashweek ,  Yun-Fei Zhu

IPC分类号： C07D495/04 ,  C07C233/88 ,  C07C235/42 ,  C07C255/57 ,  C07D213/56 ,  C07D213/61 ,  C07D213/64 ,  C07D213/70 ,  C07D213/81 ,  C07D213/84 ,  C07D213/89 ,  C07D215/14 ,  C07D215/54 ,  C07D401/04 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D239/36 ,  C07D213/58

CPC分类号： C07D495/04 ,  C07C233/88 ,  C07C235/42 ,  C07C255/57 ,  C07D213/56 ,  C07D213/58 ,  C07D213/61 ,  C07D213/64 ,  C07D213/70 ,  C07D213/81 ,  C07D213/84 ,  C07D213/89 ,  C07D215/14 ,  C07D215/54 ,  C07D239/36 ,  C07D401/04 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12

摘要： GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:




wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.